PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 177.20K | 542.40K | -714.10K | -435.40K | -150.20K |
| Total Depreciation and Amortization | 130.60K | 136.80K | 55.60K | 16.40K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.10K | -426.70K | 537.50K | 3.00K | -- |
| Change in Net Operating Assets | -203.40K | 543.70K | -350.40K | 301.00K | 9.80K |
| Cash from Operations | 90.30K | 796.20K | -471.40K | -115.00K | -140.40K |
| Capital Expenditure | -18.70K | 0.00 | 0.00 | -5.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -10.61M | -1.53M | 58.60K | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -18.70K | -10.61M | -1.53M | 53.60K | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -50.70K | -51.10K | -40.70K | -15.30K | -- |
| Issuance of Common Stock | -- | 0.00 | 7.64M | 19.86M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -35.30K | -36.50K | 5.57M | 14.50M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.20K | -9.85M | 3.57M | 14.44M | -140.40K |